These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

210 related items for PubMed ID: 16437566

  • 1. Docosahexaenoic acid reduces levodopa-induced dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys.
    Samadi P, Grégoire L, Rouillard C, Bédard PJ, Di Paolo T, Lévesque D.
    Ann Neurol; 2006 Feb; 59(2):282-8. PubMed ID: 16437566
    [Abstract] [Full Text] [Related]

  • 2. Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides.
    Tamim MK, Samadi P, Morissette M, Grégoire L, Ouattara B, Lévesque D, Rouillard C, Di Paolo T.
    Neuropharmacology; 2010 Jan; 58(1):286-96. PubMed ID: 19576910
    [Abstract] [Full Text] [Related]

  • 3. Naltrexone in the short-term decreases antiparkinsonian response to l-Dopa and in the long-term increases dyskinesias in drug-naïve parkinsonian monkeys.
    Samadi P, Grégoire L, Hadj Tahar A, Di Paolo T, Rouillard C, Bédard PJ.
    Neuropharmacology; 2005 Aug; 49(2):165-73. PubMed ID: 15996565
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. BDNF levels are not related with levodopa-induced dyskinesias in MPTP monkeys.
    Samadi P, Morissette M, Lévesque D, Di Paolo T.
    Mov Disord; 2010 Jan 15; 25(1):116-21. PubMed ID: 20014115
    [Abstract] [Full Text] [Related]

  • 6. Effect of histamine H2 receptor antagonism on levodopa-induced dyskinesia in the MPTP-macaque model of Parkinson's disease.
    Johnston TH, van der Meij A, Brotchie JM, Fox SH.
    Mov Disord; 2010 Jul 30; 25(10):1379-90. PubMed ID: 20310030
    [Abstract] [Full Text] [Related]

  • 7. Enhanced striatal opioid receptor-mediated G-protein activation in L-DOPA-treated dyskinetic monkeys.
    Chen L, Togasaki DM, Langston JW, Di Monte DA, Quik M.
    Neuroscience; 2005 Jul 30; 132(2):409-20. PubMed ID: 15802193
    [Abstract] [Full Text] [Related]

  • 8. AQW051, a novel and selective nicotinic acetylcholine receptor α7 partial agonist, reduces l-Dopa-induced dyskinesias and extends the duration of l-Dopa effects in parkinsonian monkeys.
    Di Paolo T, Grégoire L, Feuerbach D, Elbast W, Weiss M, Gomez-Mancilla B.
    Parkinsonism Relat Disord; 2014 Nov 30; 20(11):1119-23. PubMed ID: 25172125
    [Abstract] [Full Text] [Related]

  • 9. Plasmalogen precursor analog treatment reduces levodopa-induced dyskinesias in parkinsonian monkeys.
    Grégoire L, Smith T, Senanayake V, Mochizuki A, Miville-Godbout E, Goodenowe D, Di Paolo T.
    Behav Brain Res; 2015 Jun 01; 286():328-37. PubMed ID: 25771209
    [Abstract] [Full Text] [Related]

  • 10. Changes of AMPA receptors in MPTP monkeys with levodopa-induced dyskinesias.
    Ouattara B, Hoyer D, Grégoire L, Morissette M, Gasparini F, Gomez-Mancilla B, Di Paolo T.
    Neuroscience; 2010 Jun 02; 167(4):1160-7. PubMed ID: 20303391
    [Abstract] [Full Text] [Related]

  • 11. The plasmalogen precursor analog PPI-1011 reduces the development of L-DOPA-induced dyskinesias in de novo MPTP monkeys.
    Bourque M, Grégoire L, Di Paolo T.
    Behav Brain Res; 2018 Jan 30; 337():183-185. PubMed ID: 28917506
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effect of kynurenine 3-hydroxylase inhibition on the dyskinetic and antiparkinsonian responses to levodopa in Parkinsonian monkeys.
    Samadi P, Grégoire L, Rassoulpour A, Guidetti P, Izzo E, Schwarcz R, Bédard PJ.
    Mov Disord; 2005 Jul 30; 20(7):792-802. PubMed ID: 15954116
    [Abstract] [Full Text] [Related]

  • 15. Pardoprunox reverses motor deficits but induces only mild dyskinesia in MPTP-treated common marmosets.
    Johnston LC, Jackson MJ, Rose S, McCreary AC, Jenner P.
    Mov Disord; 2010 Oct 15; 25(13):2059-66. PubMed ID: 20721904
    [Abstract] [Full Text] [Related]

  • 16. Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys.
    Quik M, Cox H, Parameswaran N, O'Leary K, Langston JW, Di Monte D.
    Ann Neurol; 2007 Dec 15; 62(6):588-96. PubMed ID: 17960553
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Prevention of levodopa-induced dyskinesias by a selective NR1A/2B N-methyl-D-aspartate receptor antagonist in parkinsonian monkeys: implication of preproenkephalin.
    Morissette M, Dridi M, Calon F, Hadj Tahar A, Meltzer LT, Bédard PJ, Di Paolo T.
    Mov Disord; 2006 Jan 15; 21(1):9-17. PubMed ID: 16127720
    [Abstract] [Full Text] [Related]

  • 19. Prolonged kynurenine 3-hydroxylase inhibition reduces development of levodopa-induced dyskinesias in parkinsonian monkeys.
    Grégoire L, Rassoulpour A, Guidetti P, Samadi P, Bédard PJ, Izzo E, Schwarcz R, Di Paolo T.
    Behav Brain Res; 2008 Jan 25; 186(2):161-7. PubMed ID: 17868931
    [Abstract] [Full Text] [Related]

  • 20. Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease.
    Hill MP, Ravenscroft P, Bezard E, Crossman AR, Brotchie JM, Michel A, Grimée R, Klitgaard H.
    J Pharmacol Exp Ther; 2004 Jul 25; 310(1):386-94. PubMed ID: 15004218
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.